Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens.

Cancer immunology research - 1 Aug 2016

Prickett Todd D, Crystal Jessica S, Cohen Cyrille J, Pasetto Anna, Parkhurst Maria R, Gartner Jared J, Yao Xin, Wang Rong, Gros Alena, Li Yong F, El-Gamil Mona, Trebska-McGowan Kasia, Rosenberg Steven A, Robbins Paul F

Abstract excerpt

Immunotherapy treatment of patients with metastatic cancer has assumed a prominent role in the clinic. Durable complete response rates of 20% to 25% are achieved in patients with metastatic melanoma following adoptive cell transfer of T cells derived from metastatic lesions, responses that appear in some patients to be mediated by T cells that predominantly recognize mutated antigens. Here, we provide a detailed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epitopes, T-Lymphocyte

Share to Immunotherapy, Adoptive

Share to Melanoma

Share to T-Cell Antigen Receptor Specificity

Share to Tomography, X-Ray Computed

Source

Open in PubMed Open full text

Identifiers

PMID: 27312342
DOI: 10.1158/2326-6066.CIR-15-0215
PMCID: PMC4970903

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens.PMID 27312342Read ↗

Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.Semantic proximity Read ↗

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.Semantic proximity Read ↗

Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.Semantic proximity Read ↗

Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanomaSemantic proximity Read ↗

Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer.Semantic proximity Read ↗

Exploiting the Mutanome for Tumor VaccinationSemantic proximity Read ↗

Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma.Semantic proximity Read ↗

HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.Semantic proximity Read ↗

Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes.Semantic proximity Read ↗

Patient-derived xenografts and single-cell sequencing identifies three subtypes of tumor-reactive lymphocytes in uveal melanoma metastasesSemantic proximity Read ↗

Exome Sequencing to Predict Neoantigens in Melanoma.Semantic proximity Read ↗

PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.